D. Planchard provides an expert perspective for results and toxicity data in trials performed in advanced squamous NSCLC and reported at ASCO 2015. In particular, he elaborates results of nedaplatin plus docetaxel in advanced or relapsed setting, afatinib vs erlotinib in second-line treatment, and nivolumab vs docetaxel in previously treated advanced or metastatic squamous NSCLC.
Related Videos In Thoracic Oncology
M Patricia Rivera, CHEST 2018 – Lung cancer update
M Patricia Rivera (University of North Carolina in Chapel Hill, NC, US) provides a valuable update on lung cancer, with a focus on important points the pulmonologist needs to know and the remarkable impact of personalised therapy. Questions Part 1 1. What are the most important points the pulmonologist needs to know about the new […]
M Patricia Rivera, ATS 2018 – ATS Assembly on Thoracic Oncology
M Patricia Rivera (University of North Carolina in Chapel Hill, NC, US) is Chair of the ATS Assembly on Thoracic Oncology. Here she discusses the mission and scope of her Assembly, significant recent developments in her field and activities at ATS 2018 that have been of greatest interest. Questions 1. Tell us a little about […]
ERS 2016 Felix JF Herth
Felix JF Herth discusses the challenges of diagnosing lung cancer and provides an overview of the Archimedes procedure. FILMED AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) INTERNATIONAL CONGRESS, SEPTEMBER 2016 What are some of the clinical challenges physicians face today when diagnosing patients with lung cancer? 00:14 – So the question is where we are facing […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!